Akari Therapeutics, Plc Business Combination, Acquisition Related Costs
Akari Therapeutics, Plc (AKTX) reported Business Combination, Acquisition Related Costs of $3.27 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:BusinessCombinationAcquisitionRelatedCosts · last filed 2026-03-30
- Akari Therapeutics, Plc business combination, acquisition related costs for the quarter ending 2024-12-31 was $983.00K.
- Akari Therapeutics, Plc business combination, acquisition related costs for the quarter ending 2024-09-30 was $992.00K.
- Akari Therapeutics, Plc business combination, acquisition related costs for the quarter ending 2024-06-30 was $254.00K.
- Akari Therapeutics, Plc business combination, acquisition related costs for fiscal 2024 was $3.27M.
| Period end | Business Combination, Acquisition Related Costs 3 month | Business Combination, Acquisition Related Costs 6 month | Business Combination, Acquisition Related Costs 9 month | Business Combination, Acquisition Related Costs 12 month |
|---|---|---|---|---|
| 2024-12-31 | $983.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $1.98M derived: sum of 2 quarters · filed 2026-03-30 | $2.23M derived: sum of 3 quarters · filed 2026-03-30 | $3.27M 10-K · filed 2026-03-30 |
| 2024-09-30 | $992.00K 10-Q · filed 2025-11-13 | $1.25M derived: sum of 2 quarters · filed 2025-11-13 | $2.29M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $254.00K 10-Q · filed 2025-08-13 | $1.30M 10-Q · filed 2025-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |